今日观察！A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.

全民目击IP强势回归 电影《过渡空间》暑期震撼上映

2024年8月1日，由紫东佳映影业、北京二十一世纪威克传媒、北京真桐影视传媒联合出品的奇幻类型情感大片《过渡空间》将在全国各大影院震撼上映。该片作为国民级IP“全民目击”的续作IP，由国际影后余男、柏林影帝王景春、实力偶像蔡珩领衔主演，黄奕、赵达、马浴柯、黄小蕾、丛珊等众多实力派明星联袂主演，偶像女神关雪盈特别主演。影片由著名导演非行执导，延续了“全民目击”系列一贯的品质和口碑，为观众带来了一场精彩绝伦的视听盛宴。

电影《过渡空间》讲述了林泰（王景春 饰）在女儿林萌萌（关雪盈 饰）意外身亡后，为了查明真相而踏入了一个奇幻的“过渡空间”的故事。在这个空间里，时间和空间都失去了意义，林泰经历了各种离奇的事件，也逐渐揭开了女儿死亡背后的真相。影片融合了奇幻、悬疑、情感等多种元素，在烧脑的剧情中探讨了人性、亲情、爱情等深刻主题，引发了观众的强烈共鸣。

作为“全民目击”系列的续作IP，《过渡空间》在制作上精益求精，力求为观众带来最完美的观影体验。影片的导演非行曾执导过电影《全民目击》和电视剧《全民目击之生存游戏》，对该系列有着深刻的理解和掌控。此次执导《过渡空间》，他大胆突破了以往的创作风格，在奇幻的背景下融入现实思考，为影片注入了新鲜的血液。

在演员阵容方面，《过渡空间》汇集了众多实力派明星。王景春凭借精湛的演技，将林泰这个父亲的复杂情感演绎得淋漓尽致。柏林影帝王景春则颠覆了以往的硬汉形象，饰演了一位深情款款的父亲。实力偶像蔡珩饰演的林萌萌，青春靓丽，充满活力。黄奕、赵达、马浴柯、黄小蕾、丛珊等众多实力派明星的加盟，也为影片增添了不少亮点。

电影《过渡空间》的上映，不仅是“全民目击”系列IP的强势回归，也是中国电影市场的一次大胆创新。影片以奇幻的视角，探讨了现实的主题，引发了观众的思考。相信这部电影一定会在暑期档掀起观影热潮，为观众带来难忘的观影体验。